Purpuric drug eruption possibly due to gefinitib (Iressa®)

被引：20
作者：
Kurokawa, I
Endo, K
Hirabayashi, M
机构：
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2005年 / 44卷 / 02期
关键词：
D O I：
10.1111/j.1365-4632.2005.02185.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：167 / 168
页数：2
相关论文
共 4 条
[1]  
Baselga J, 2000, J CLIN ONCOL, V18, p54S
[2]   Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 [J].
Busam, KJ ;
Capodieci, P ;
Motzer, R ;
Kiehn, T ;
Phelan, D ;
Halpern, AC .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) :1169-1176
[3]   COMPARISON OF EPIDERMAL GROWTH-FACTOR BINDING AND RECEPTOR DISTRIBUTION IN NORMAL HUMAN-EPIDERMIS AND EPIDERMAL APPENDAGES [J].
NANNEY, LB ;
MAGID, M ;
STOSCHECK, CM ;
KING, LE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 83 (05) :385-393
[4]   Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor [J].
van Doorn, R ;
Kirtschig, G ;
Scheffer, E ;
Stoof, TJ ;
Giaccone, G .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (03) :598-601
1